Literature DB >> 12466135

Serotonin mechanisms in heart valve disease II: the 5-HT2 receptor and its signaling pathway in aortic valve interstitial cells.

Jie Xu1, Bo Jian, Richard Chu, Zhibin Lu, Quanyi Li, John Dunlop, Sharon Rosenzweig-Lipson, Paul McGonigle, Robert J Levy, Bruce Liang.   

Abstract

Serotonin [5-hydroxytryptamine (5-HT)]-mediated cardiac valvular disease has been commonly observed in patients with carcinoid tumors. Previous research by others using reverse transcriptase-polymerase chain reaction demonstrated that aortic valve cells expressed predominantly 5-HT(2A/2B) receptors (5-HT(2A)R). Related investigations by our group using sheep aortic valve interstitial cell (SAVIC) cultures demonstrated that 5-HT both up-regulates transforming growth factor (TGF)-beta1 expression and activity, and also results in increased phospholipase C (PLC) activity. Thus, the present study investigated the hypothesis that the 5-HT signaling pathway in SAVICs involves 5-HT(2)Rs with associated G-protein signal transduction. The objectives were to functionally characterize in SAVIC cultures the native serotonin receptor subtypes using specific agonists and antagonists, and to delineate the serotonin-signaling pathway. 5-HT administration caused a marked stimulation of PLC activity. SAVIC studies of specific agents that target the 5-HT(2)R subtypes indicate that this response seemed to be mediated predominantly by 5-HT(2A)Rs. Furthermore, the sheep 5-HT(2A)R was identified by reverse transcriptase-polymerase chain reaction with sequence confirmation including comparisons to pig and human 5-HT(2A)R. Extracellular signal-regulated kinase (Erk 1/2) is a signaling molecule downstream from the 5-HT(2A)R. Both a protein kinase C inhibitor, GF109203X, and a Src inhibitor, PP1, attenuated 5-HT-stimulated Erk 1/2 activation. However, a 5-HT(2A)R antagonist, MDL 100907, inhibited 5-HT up-regulation of PLC and TGF-beta1, while having far less pronounced effects on Erk 1/2. In conclusion, these studies of the signal transduction activity of SAVICs in response to 5-HT have demonstrated that the 5-HT(2A)Rs are the most functionally active of the 5-HT(2)Rs in this cell type. Furthermore, 5-HT(2A)Rs are also involved in 5-HT up-regulation of active TGF-beta. 5-HT also mediated strong Erk 1/2 signaling via the MAP-kinase pathway, which was only in part because of 5-HT(2A)R activity. Thus, major 5-HT Erk 1/2 signaling beyond that controlled by 5-HT(2)Rs must involve other serotonin receptor types and/or secondary signaling events.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466135      PMCID: PMC1850896          DOI: 10.1016/S0002-9440(10)64497-5

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  45 in total

1.  SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist.

Authors:  G A Kennett; M D Wood; F Bright; B Trail; G Riley; V Holland; K Y Avenell; T Stean; N Upton; S Bromidge; I T Forbes; A M Brown; D N Middlemiss; T P Blackburn
Journal:  Neuropharmacology       Date:  1997 Apr-May       Impact factor: 5.250

Review 2.  Mitogen-activated protein kinase cascades and regulation of gene expression.

Authors:  B Su; M Karin
Journal:  Curr Opin Immunol       Date:  1996-06       Impact factor: 7.486

Review 3.  Regulation of transcription by MAP kinase cascades.

Authors:  R Treisman
Journal:  Curr Opin Cell Biol       Date:  1996-04       Impact factor: 8.382

4.  Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases.

Authors:  L M Luttrell; B E Hawes; T van Biesen; D K Luttrell; T J Lansing; R J Lefkowitz
Journal:  J Biol Chem       Date:  1996-08-09       Impact factor: 5.157

5.  BW 723C86, a 5-HT2B receptor agonist, causes hyperphagia and reduced grooming in rats.

Authors:  G A Kennett; K Ainsworth; B Trail; T P Blackburn
Journal:  Neuropharmacology       Date:  1997-02       Impact factor: 5.250

Review 6.  5-HT2 receptor subtypes: a family re-united?

Authors:  G Baxter; G Kennett; F Blaney; T Blackburn
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

7.  Receptor binding properties of amperozide.

Authors:  J Svartengren; P Simonsson
Journal:  Pharmacol Toxicol       Date:  1990

8.  Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.

Authors:  P A Robiolio; V H Rigolin; J S Wilson; J K Harrison; L L Sanders; T M Bashore; J M Feldman
Journal:  Circulation       Date:  1995-08-15       Impact factor: 29.690

9.  In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Authors:  G A Kennett; M D Wood; F Bright; J Cilia; D C Piper; T Gager; D Thomas; G S Baxter; I T Forbes; P Ham; T P Blackburn
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

10.  Involvement of transforming growth factor-beta in the formation of fibrotic lesions in carcinoid heart disease.

Authors:  J Waltenberger; L Lundin; K Oberg; E Wilander; K Miyazono; C H Heldin; K Funa
Journal:  Am J Pathol       Date:  1993-01       Impact factor: 4.307

View more
  30 in total

1.  Serotonin mechanisms in heart valve disease I: serotonin-induced up-regulation of transforming growth factor-beta1 via G-protein signal transduction in aortic valve interstitial cells.

Authors:  Bo Jian; Jie Xu; Jeanne Connolly; Rashmin C Savani; Navneet Narula; Bruce Liang; Robert J Levy
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  Aortic Valve Regurgitation: Pathophysiology and Implications for Surgical Intervention in the Era of TAVR.

Authors:  Filippo Ravalli; Alexander P Kossar; Hiroo Takayama; Juan B Grau; Giovanni Ferrari
Journal:  Struct Heart       Date:  2020-01-23

Review 3.  The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology.

Authors:  Amber C Liu; Vineet R Joag; Avrum I Gotlieb
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

4.  Aortic valve cyclic stretch causes increased remodeling activity and enhanced serotonin receptor responsiveness.

Authors:  Kartik Balachandran; Marina A Bakay; Jeanne M Connolly; Xuemei Zhang; Ajit P Yoganathan; Robert J Levy
Journal:  Ann Thorac Surg       Date:  2011-07       Impact factor: 4.330

5.  The role of 5-HT2B receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors.

Authors:  Estelle Ayme-Dietrich; Roland Lawson; Francine Côté; Claudia de Tapia; Sylvia Da Silva; Claudine Ebel; Béatrice Hechler; Christian Gachet; Jérome Guyonnet; Hélène Rouillard; Jordane Stoltz; Emily Quentin; Sophie Banas; François Daubeuf; Nelly Frossard; Bernard Gasser; Jean-Philippe Mazzucotelli; Olivier Hermine; Luc Maroteaux; Laurent Monassier
Journal:  Br J Pharmacol       Date:  2017-10-15       Impact factor: 8.739

Review 6.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

Review 7.  Serotonin receptors and heart valve disease--it was meant 2B.

Authors:  Joshua D Hutcheson; Vincent Setola; Bryan L Roth; W David Merryman
Journal:  Pharmacol Ther       Date:  2011-04-02       Impact factor: 12.310

8.  Serotonin receptor 2B signaling with interstitial cell activation and leaflet remodeling in degenerative mitral regurgitation.

Authors:  Kathryn H Driesbaugh; Emanuela Branchetti; Juan B Grau; Samuel J Keeney; Kimberly Glass; Mark A Oyama; Nancy Rioux; Salma Ayoub; Michael S Sacks; John Quackenbush; Robert J Levy; Giovanni Ferrari
Journal:  J Mol Cell Cardiol       Date:  2017-12-30       Impact factor: 5.000

9.  Fibronectin-based isolation of valve interstitial cell subpopulations: relevance to valve disease.

Authors:  Elizabeth H Stephens; Thanh N Huynh; Jennifer D Cieluch; K Jane Grande-Allen
Journal:  J Biomed Mater Res A       Date:  2010-01       Impact factor: 4.396

Review 10.  The use of lorcaserin in the management of obesity: a critical appraisal.

Authors:  Bo Bai; Yu Wang
Journal:  Drug Des Devel Ther       Date:  2010-12-20       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.